Latest News
Inhibrx's ozekibart BLA accepted by FDA for chondrosarcoma treatment
15 June 2026 - Inhibrx Biosciences Inc (Nasdaq: INBX) disclosed on Monday that it has received U.S. Food and Drug Administration acceptance of its Biologics License Application for ozekibart (INBRX-109) for the treatment of patients with unresectable...
Sensei Biotherapeutics changes name to Faeth Therapeutics
15 June 2026 - Clinical-stage biotechnology company Sensei Biotherapeutics Inc (Nasdaq:SNSE) announced on Monday that it has changed its corporate name to Faeth Therapeutics Inc, with its common stock expected to begin trading under the ticker symbol...
Bayer receives FDA approval for AMBELVIST MRI contrast agent
15 June 2026 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) said on Monday that it has received US Food and Drug Administration (FDA) approval for AMBELVIST (gadoquatrane), an intravenous macrocyclic gadolinium-base...
Johnson & Johnson commits over USD1bn to expand Vision manufacturing in Jacksonville
15 June 2026 - Healthcare products company Johnson & Johnson (NYSE:JNJ) on Monday announced an investment of more than USD1bn to strengthen its Vision operations in Jacksonville, Florida, expanding US-based manufacturing, packaging, and distribut...
Genmab reports strong epcoritamab results in elderly newly diagnosed DLBCL patients
15 June 2026 - Danish biotechnology company Genmab A/S (CPH:GMAB) on Monday reported data from the Phase 2 EPCORE DLBCL-3 and Phase 1b/2 EPCORE NHL-2 studies showing high response rates for epcoritamab-based treatments in elderly patients with newly ...